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Introduction
Overt abnormalities in thyroid function are common 
endocrine disorders affecting 5-10% of individuals over 
a lifespan.[1] Clinical symptoms and signs are often 
nonspecific, and the diagnosis and monitoring of therapy 
depends crucially on measurements of thyroid hormones 
(triiodothyronine, T3 and thyroxine, T4), and thyroid 
stimulating hormone (TSH) in blood.[2] Minor abnormalities 
in thyroid function with subclinical hypothyroidism or 
hyperthyroidism are even more common.[3,4] Both subclinical 
hypothyroidism and hyperthyroidism are associated with 
an increase in risk of disease,[3,4] as well as abnormalities 
in biochemical and physiologic measures that are often 
abnormal in patients with overt thyroid disease.[5] 
Both subclinical hyperthyroidism and hypothyroidism 
are increasingly being recognized as having significant 
health implications with subclinical hypothyroidism more 
common than subclinical hyperthyroidism.[6] Subclinical 
hypothyroidism is defined by the finding of elevated serum 
TSH concentrations associated with normal free thyroid 
hormone levels (FT4 and FT3).
[7] The prevalence of this 
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condition is higher in women than men and increases with 
age, reaching a peak of 21% in women and 16% in men 
over 74 years of age.[8,9] 
The serum creatine kinase (CK) activity in healthy 
individuals depends on age, race, lean body mass and 
physical activity.[10] It has since become an important clinical 
marker for muscle damage. Musculoskeletal disorders 
often accompany thyroid dysfunction. The association 
of myopathy with both myxedema and thyrotoxicosis is 
well known.[11] Concentrations of CK in serum are often 
increased in patients with primary hypothyroidism,[12,13] 
but evidence for any change in thyrotoxicosis is conflicting. 
Some authors[14] reported normal and others subnormal[15] 
CK activity. Furthermore only a few studies have investigated 
serum lactate dehydrogenase (LDH) activity in patients with 
thyroid dysfunction.[16,17]
In recent years studies have been conducted to establish 
a relationship of CK activity in thyroid diseases.[18] 
However, no correlation has been consistently described 
between CK activity and circulating concentrations of 
either T3, T4, or TSH.
[19-21] The aims of this study were to 
determine serum activities of CK and LDH in overt and 
subclinical hypothyroidism, and also in overt and subclinical 
hyperthyroidism; to evaluate the relationship between 
FT4, and TSH levels and the degree of skeletal muscle 
involvement in these thyroid disorders, as determined by 
serum CK activity in these thyroid dysfunctions. 
Materials and Methods
This is a retrospective study where information was 
extracted from the medical records of newly diagnosed 
hypothyroidism or hyperthyroidism patients attending the 
Endocrinology Clinic at the University Hospital of the West 
Indies from 2005-2009.
Exclusion criteria were previous use of L-thyroxine or 
antithyroid medication and thyroidectomy. Also, patients 
with risk factors for having high CK activity were excluded: 
recent fall, intoxication, intramuscular injection, seizure, 
stroke, surgery, excessive physical exercise, and certain 
medications (antiarrhythmics, β-blockers, lithium, fibrates, 
phenothiazines, steroids and statins). We included 18 
patients (14 females, 4 males) with overt hypothyroidism; 
50 patients (34 females, 16 male) with subclinical 
hypothyroidism; 31 patients (26 females, 5 males) with 
overt hyperthyroidism; 61 patients (46 females, 15 male) 
with subclinical hyperthyroidism, and 99 controls (healthy 
persons who did their annual routine tests; 64 females and 
25 males) in the study. Serum levels of TSH and FT4 were 
measured by radioimmunoassay on AXSYM System (Abbott 
Laboratories, Abbott Park, USA); serum CK and LDH 
activities were determined using an automated analyzer 
(c8000, Abbott Architect, Abbot Park, Illinois, USA) in 
all subjects.
The patients in the study were classified into one of the 
following four groups based on their thyroid function tests 
These were (1) overt thyrotoxicosis defined as a TSH level 
of less than 0.40 mU/L (normal, 0.4 – 4.0 mU/L) with an 
elevated FT4 concentration (normal, 0.8 – 1.9 ng/dL); (2) 
subclinical hyperthyroidism defined as a TSH level of less 
than 0.40 mU/L with a normal FT4 concentration; (3) 
subclinical hypothyroidism defined as a TSH level of more 
than 4.0 mU/L and less than 20 mU/L with a normal FT4 
concentration; and (4) overt hypothyroidism was defined 
as a TSH level of 20 mU/L or more or a TSH level of more 
than 4.0 mU/L with an FT4 concentration below normal.[22]
Chi-square was used to examine non-metric variables. A 
P-value < 0.05 (two-tailed) was used to establish statistical 
significance. Statistical analyses were carried out using linear 
regression analysis.
Results
Patient groups (overt hypothyroidism and subclinical 
hypothyroidism; overt hyperthyroidism and subclinical 
hyperthyroidism) and control groups were similar in 
regard to age (60.67 ± 17.96 and 59.16 ± 21.16; 58.38 ± 
18.33 and 58.65 ± 17.91 years) and 52.75 ± 16.44 years, 
respectively; and gender (16/4 and 34/16; 26/5 and 46/15) 
and 64/25, female/male, respectively. 
Elevation of CK activity was found in 5 patients (28%, 5/18) 
with overt hypothyroidism and in 12 patients (24.0%, 12/50) 
with subclinical hypothyroidism. The mean CK activity in 
subclinical hypothyroid patients was 179.80 ± 125.68 U/L 
compared with 389.901 ± 381.20 U/L in overt hypothyroid 
patients [Table 1]; while values for patients with overt and 
subclinical hyperthyroidism was 88.37 ± 69.22 U/L and 
105.98 ± 57.00 U/L respectively [Table 2].
Elevation of LDH activity was found in 6 patients (33.3%, 
6/18) with overt hypothyroidism and in 37 patients (74.0%, 
37/50) with subclinical hypothyroidism. The mean LDH 
activity in subclinical hypothyroid patients was 340.38 
± 153.38 compared with 421.00 ± 203.91 U/L in overt 
hypothyroid patients [Table 1]; while values for patients 
with overt and subclinical hyperthyroidism were 233.80 ± 
77.37 U/L and 227.81 ± 54.99 U/L respectively [Table 2].
In the hypothyroid patients, a positive correlation was 
found between CK activity and TSH levels (r = 0.292, p 
= 0.015), and a negative correlation between CK activity 
and FT4 concentration (r = - 0.325, P = 0.007); and 
between FT4 concentration and TSH levels (r = - 0.371, P 
= 0.002). No significant correlations were found between 
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FT4 concentration and LDH activity (P = 0.836), between 
TSH levels and LDH activity (P = 0.714), between CK and 
LDH activities (P = 0.133).
There was statistically significant difference in CK and 
LDH activities in patients with overt hypothyroidism 
and the control, and subclinical hypothyroidism and the 
control [Table 1]. Although a statistically significant 
elevation of FT4 concentration was found in patients with 
overt hyperthyroidism when compared with the subclinical 
hyperthyroidism patients (P = 0.0001); no statistical 
difference was found for TSH, CK, and LDH [Table 2].
In the hyperthyroid patients compared with the control 
group, CK activity was found not to be statistically significant 
in the subclinical and the control (P = 0.326), and the overt 
and the control group (P = 0.147). However, significant 
statistical differences in levels were found in FT4, TSH and 
LDH activity between the subclinical and the control; and 
the overt hyperthyroidism and the control group [Tables 2]. 
However, no statistical correlation was found between FT4 
and TSH (P = 0.128), CK and FT4 (P = 0.120) and LDH 
and FT4 (P = 0.545) in hyperthyroid patients; a positive 
correlation existed between CK and LDH activities (r = 
0.341, P = 0.021). A significant statistical difference was 
found among the means of CK activity for the hyperthyroid 
and hypothyroid patients, and control group [Table 3]. 
Discussion
The findings of this study confirm that elevated serum 
CK activity is frequently increased in hypothyroidism and 
decreased in hyperthyroidism. This study also indicates that 
CK activity correlates with the degrees of hypothyroidism 
and hyperthyroidism, as evident by the magnitude of 
Table 1: Comparison of FT
4
, TSH, CK, and LDH levels between controls, overt and subclinical hypothyroid patients
Variables Subclinical hypothyroidism (n = 59) Overt hypothyroidism (n = 10) P value
FT
4
1.04 ± 0.29 0.38 ± 0.15 0.0001
TSH 16.08 ± 40.98 70.52 ± 99.22 0.004
CK 179.80 ± 125.68 389.90 ± 381.20 0.001
LDH 340.38 ± 153.38 421.00 ± 203.91 0.106
Subclinical hypothyroidism (n = 59) Control group (n = 100)
FT
4
1.04 ± 0.29 1.22 ± 0.21 <0.0001
TSH 16.08 ± 40.98 1.64 ± 0.59 0.003
CK 179.80 ± 125.68 102.19 ± 46.41 <0.0001
LDH 340.38 ± 153.38 202.85 ± 36.06 <0.0001
Overt hypothyroidism (n = 10) Control group (n = 100)
FT
4
0.38 ± 0.15 1.22 ± 0.21 <0.0001
TSH 70.52 ± 99.22 1.64 ± 0.59 0.012
CK 389.90 ± 381.20 102.19 ± 46.41 0.007
LDH 421.00 ± 203.91 202.85 ± 36.06 0.0003
FT4 = Free thyroid; TSH = Thyroid stimulating hormone; and LDH = lactate dehydrogenase; CK = Creatine kinase
Table 2: Comparison of FT
4
, TSH, CK, and LDH levels between controls, overt and subclinical hyperthyroid patients
Variables Subclinical hyperthyroidism (n = 62) Overt hyperthyroidism (n = 31) P value
FT
4
1.37 ± 0.46 4.02 ± 1.94 0.0001
TSH 0.34 ± 1.28 0.05 ± 0.08 0.086
CK 105.98 ± 57.00 88.37 ± 69.22 0.238
LDH 227.81 ± 54.99 233.80 ± 77.37 0.794
Subclinical hyperthyroidism (n = 62) Control group (n = 100)
FT
4
1.37 ± 0.46 1.22 ± 0.21 0.007
TSH 0.34 ± 1.28 1.64 ± 0.59 <0.0001
CK 105.98 ± 57.00 102.19 ± 46.41 0.326
LDH 227.81 ± 54.99 202.85 ± 36.06 0.001
Overt hyperthyroidism (n = 31) Control group (n = 100)
FT
4
4.02 ± 1.94 1.22 ± 0.21 <0.0001
TSH 0.05 ± 0.08 1.64 ± 0.59 <0.0001
CK 88.37 ± 69.22 102.19 ± 46.41 0.147
LDH 233.80 ± 77.37 202.85 ± 36.06 0.012
FT4 = Free thyroid; TSH = Thyroid stimulating hormone; and LDH = lactate dehydrogenase; CK = Creatine kinase
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the TSH. Elevated serum CK activity was observed in 
hypothyroid patients, and was higher in patients with overt 
hypothyroidism, and less so in subclinical hypothyroid 
patients. These findings are in accordance with those of other 
studies, which report a 43% to 97% elevation of serum CK 
activity in hypothyroidism: Beyer et al, 43%[22] Giampietro 
et al, 90%[19] and Soufir et al,[23] 97%. This is in contrast to the 
findings of Hartl et al, who found an elevation of CK activity 
in only 2 of 69 patients (3%), one with overt and one with 
subclinical hypothyroidism. [24] The finding of decreased CK 
activity in patients with hyperthyroidism compared with 
controls is in accordance with other studies.[14,25] 
In a few of the severely hypothyroid patients with TSH 
exceeding 40 mU/mL, the increase in serum CK activity was 
pronounced with CK values over 500 U/L. Unexpectedly, 
normal CK values was observed in older patients, despite 
marked overt hypothyroidism could presumably be related 
to inter-individual variations,[26] for example due to reduced 
muscle mass and lack of physical activity. Nonspecific 
muscle stiffness related to myalgia may be associated with 
serum muscle enzyme elevations. Skeletal muscle is affected 
more profoundly in patients with overt hypothyroidism, 
less so when subclinical hypothyroidism is present.[27] 
However, clinical muscular symptoms are not usually the 
chief complaint at presentation. More than 40% of patients 
with hypothyroidism also had neuromuscular complaints at 
the time of diagnosis.[28]
Some patients with primary hypothyroidism may have a 
marked myopathy,[29] with associated histological changes 
in muscle cells.[11] It is widely suggested that this increase 
results from leakage of the enzyme from muscle cells,[30] 
perhaps related to the subnormal body temperature 
accompanying primary hypothyroidism.[31] The increase may 
also reflect a decrease in enzyme clearance.[32] 
Various mechanisms have been proposed as causing 
elevated CK activity in hypothyroidism, although these 
mechanisms may have varying influence at different 
stages of the disease. [19,20] The hypo-metabolic state of 
hypothyroidism can cause a reduction in glycolysis and 
oxidative phosphorylations and thus reducing adenosine 
triphosphate (ATP) concentrations beyond a critical 
limit. The alteration in sarcolemmal membranes can cause 
increased cell permeability and the leakage of CK from 
cells.[33,34] Another possibility is reduced turnover of CK 
because of hypothyroidism, allowing serum activities to 
rise generating a marked release of CK through the altered 
sarcolemnal membranes.[31]
Our finding of lower CK activity in hyperthyroidism, is in 
accordance with other reports[14,25] and suggests that in 
the hypermetabolic state there may be increased enzyme 
degradation which may have contributed to these low CK 
activity. That the muscle cell is less permeable than normal 
to efflux of CK in hyperthyroidism is unlikely, although 
possibly in these circumstances the muscle cell might reflect 
loss of muscle bulk.[25]
A key finding in the study is significant inverse correlation 
in hypothyroid patients between serum CK and TSH (P 
< 0.001), regardless of whether FT4 concentrations were 
normal (P < 0.01) or decreased (P < 0.01). The elevated 
CK activity in subclinical hypothyroid patients might 
be explained by the fact that just as the pituitary gland 
releases TSH in response to suboptimal levels of thyroid 
hormones, the muscles probably respond by releasing CK 
into the circulation.[22] Further, the results of this study are in 
accordance with others[22,35,36] as we found that the severity 
of hypothyroidism to correlate with the elevation of serum 
CK activities: however, still others have not found such a 
relationship[23,24,28] or have found a reciprocal relationship. [37] 
These conflicting results may depend more on the degree 
of clinical manifestations of hypothyroidism, rather than on 
the amount of elevation of serum markers.
Hypothyroid patients have increased activity of creatine 
kinase that is mostly due to increased CK-MM as CK 
isoenzyme analysis in six cases of primary hypothyroidism 
showed only the MM isoenzyme to be present in four 
patients, and MM with a trace of MB in the other two.[38] 
These findings also confirm previous studies that indicated 
skeletal muscle to be the major source of the increased 
plasma CK activity.[39,40]
Studies have shown that LDH activity was increased 
and decreased in the hypo- and hyperthyroid states, 
Table 3: Descriptive statistics of hyperthyroidism (subclinical and overt) and hypothyroidism (subclinical and 















FT41 1.37 (0.46) 4.02 (1.94) 1.04 (0.29) 0.38 (0.15) 1.22 (0.21)
TSH2 0.34 (1.28) 0.005 (0.08) 16.08 (40.98) 70.52 (99.22) 1.64 (0.59)
CK3 105.98 (57.00) 88.37 (69.22) 179.80 (125.68) 389.90 (381.20) 102.19 (46.41)
LDH4 227.81 (55.00) 233.80 (77.37) 340.38 (153.38) 421.00 (203.91) 202.85 (36.06)
1F-statistic = 109.60, P < 0.0001; 2F-statistic = 18.06, P < 0.0001; 3F-statistic = 22.13, P < 0.0001; 4F-statistic = 18.69, P < 0.0001
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respectively. [16,17] The study found increase in LDH activity 
in patients with hypothyroidism which correlates with the 
degree of hypothyroidsm. LDH activity have been reported 
to be increased in primary hypothyroidism[41,42] and in one 
study, 37% of hypothyroid patients had elevated LDH.[39] In 
another study of six untreated primary hypothyroid patients, 
LDH activities from 473 to 1885 U/L[38] was reported; and 
in a latter study 27 of 45 hypothyroid patients had elevated 
total LDH levels.[43] Further isoenzme analysis showed a 
normal pattern of LDH isozyme in 12 patients, while in the 
remaining ten, three showed increased LDH1 levels, one 
showed an increased lactate dehydrogenase isozyme 3 level 
(LDH3), and six showed elevated
 lactate dehydrogenase 
isozyme 5 (LDH5) levels.
[43] Studies of LDH isozymes in 
myxedema heart disease have shown that LDH isozyme 
1 (LDH1) may be elevated in this disorder
 and gradually 
fade with thyroid replacement therapy.[44] The elevations 
of LDH levels could reflect increased release and/or 
decreased clearance from the liver.[45] In addition, lactate 
dehydrogenase values were inversely related to both the 
thyroxine and triiodothyronine concentrations. The finding 
of the latter study differ from others in that the LDH levels 
was statistically significantly higher than the control group 
in both patients with subclinical and over hyperthyroidism 
as significant number of these patients had normal LDH. 
Strasberg reported no association of hyperthyroidism with 
elevated levels of the LDH isozyme.[46]
Conclusion
The study found an inverse relation in the serum levels 
of FT4 concentration and serum CK activity in thyroid 
diseases; and between FT4 concentration and LDH activity 
in hypothyroidism. In hypothyroid patients with decrease in 
serum FT4 concentration, there is a significant increase in 
CK and LDH activities, which indicates that these can be 
used as parameters for screening hypothyroid patients and 
to lesser extent hyperthyroid patients. 
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